Kodiak Sciences Inc.
KOD
शेयरों में रैंक
#3241
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
शेयर मूल्य
$86.45
मार्केट कैप
$5.43B
बदलाव (1 दिन)
-1.45%
बदलाव (1 वर्ष)
378.92%
देश
US
व्यापार Kodiak Sciences Inc. (KOD)
श्रेणी
Healthcare
Kodiak Sciences Inc. (KOD) के लिए स्टॉक मूल्य इतिहास
दिन का सबसे उच्च समापन मूल्य: $91.77 (2026-10-01 को)
दिन का सबसे निम्न समापन मूल्य: $1.97 (2018-10-01 को)
दिन का सबसे निम्न समापन मूल्य: $1.97 (2018-10-01 को)
Kodiak Sciences Inc. के स्टॉक मूल्य का इतिहास 2018 से 2026 तक
प्रत्येक वर्ष के अंत में स्टॉक मूल्य प्रदर्शन
| वर्ष | प्रदर्शन |
|---|---|
| 2026 (TTM) | 40.97% |
| 2025 | 191.32% |
| 2024 | 200.90% |
| 2023 | -58.27% |
| 2022 | -59.80% |
| 2021 | -36.18% |
| 2020 | 106.84% |
| 2019 | 776.39% |
| 2018 | 0.00% |
समान कंपनियों या प्रतिस्पर्धियों के स्टॉक मूल्य
| कंपनी | स्टॉक मूल्य | परिवर्तन 1व% | देश |
|---|---|---|---|
| $536.73 | 25.86% |
US
|
|
| $225.94 | 741.49% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $878.85 | 7.94% |
NL
|
